A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000030389

Enrollment

Unknown

Registered

2020-03-01

Start date

2020-02-29

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Exposure group:Western medicine routine treatment+triple energizer treatment

Control group:Conventional medicine routine treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with Novel coronavirus pneumonia who are mainly admitted to hospitals in Hubei Province and whose temperature is normal for at least 5 days after treatment, whose vital signs are stable (including to be discharged) or who have been discharged, but whose lung damage has not improved. 1. Aged >=18 years male and female; 2. Clinically diagnosed and confirmed cases; 3. Classification: clinically diagnosed cases, confirmed cases of ordinary, severe, critical.

Exclusion criteria

Exclusion criteria: 1. Other pneumonia; 2. Known to be allergic to traditional Chinese medicine ingredients, or patients with allergies; 3. Women during lactation and pregnancy, or have a positive urine pregnancy test.

Design outcomes

Primary

Measure	Time frame
Lung CT;TCM symptoms;	—

Secondary

Measure	Time frame
Blood routine;Respiratory antibody combination;Renal function;liver function;CRP;PCT;Cytokine (IL-6);	—

Countries

China

Contacts

Public ContactJianzhong Liu

Hubei Provincial Hospital of TCM

ljzwd@163.com+86 13307173928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026